Loading...
XJPX
2395
Market cap485mUSD
Dec 05, Last price  
1,813.00JPY
1D
-2.37%
1Q
6.96%
Jan 2017
209.39%
IPO
70.23%
Name

Shin Nippon Biomedical Laboratories Ltd

Chart & Performance

D1W1MN
XJPX:2395 chart
P/E
15.33
P/S
2.33
EPS
118.30
Div Yield, %
2.76%
Shrs. gr., 5y
—
Rev. gr., 5y
17.36%
Revenues
32.41b
+22.55%
13,805,373,00017,289,403,00019,647,248,00019,540,215,00019,050,317,00017,371,947,00015,273,969,00017,154,051,00016,926,397,00017,835,036,00014,750,072,00017,244,496,00016,600,550,00015,658,678,00014,561,084,00015,110,548,00017,748,482,00025,090,903,00026,450,468,00032,413,807,000
Net income
4.92b
-10.96%
267,412,000543,769,000599,874,000-205,549,000534,529,000-1,442,021,000-3,304,109,000-1,152,876,000-754,991,000-1,385,737,0002,646,136,000-915,938,000-3,555,948,0001,950,307,0002,550,379,0003,661,855,0007,127,629,0006,060,057,0005,531,261,0004,924,847,000
CFO
7.04b
+233.94%
755,051,000448,686,0003,166,398,000868,691,0001,743,584,000306,770,000-1,033,185,00090,290,000-1,620,133,000-2,156,044,000-3,339,930,000-849,807,0001,344,254,0002,892,655,0003,018,289,0004,746,687,0005,952,778,0004,004,019,0002,106,732,0007,035,243,000
Dividend
Mar 30, 202630 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
URL
https://www.snbl.co.jp/
IPO date
Mar 08, 2004
Employees
1,360
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT